NYSE: PFEPfizer Inc Stock
$25.78+0.22 (+0.86%)
Updated Jul 10, 2025
PFE Price
$25.78
Fair Value Price
N/A
Market Cap
$146.57B
52 Week Low
$20.92
52 Week High
$31.54
P/E
18.55x
P/B
1.62x
P/S
2.29x
PEG
0.6x
Dividend Yield
4.93%
Revenue
$62.46B
Earnings
$7.88B
Gross Margin
72.3%
Operating Margin
11.8%
Profit Margin
12.6%
Debt to Equity
1.3
Operating Cash Flow
$14B
Beta
0.42
Next Earnings
Aug 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PFE Overview
Pfizer Inc. develops and manufactures medicines and vaccines in many therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands, biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands, and sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. Pfizer was founded in 1849 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PFE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
PFE
Ranked#10 of 18
Ranked#10 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $123.73 | A | |
| $157.69 | A | |
| $9.75 | A |
Be the first to know about important PFE news, forecast changes, insider trades & much more!
PFE News
Overview
Due Diligence Score
–
Industry Average (44)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PFE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PFE ($25.78) is trading above its intrinsic value of $22.96, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PFE is good value based on its earnings relative to its share price (18.55x), compared to the US market average (30.8x)
P/E vs Market Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more PFE due diligence checks available for Premium users.
Valuation
PFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.55x
Industry
38.78x
Market
30.8x
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
6.11x
PFE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PFE price to earnings growth (PEG)
For valuing profitable companies with growth potential
PFE is good value based... subscribe to Premium to read more.
PEG Value Valuation
PFE's financial health
Profit margin
Revenue
$13.7B
Net Income
$3.0B
Profit Margin
21.6%
PFE's Earnings (EBIT) of $7.37B... subscribe to Premium to read more.
Interest Coverage Financials
PFE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$208.0B
Liabilities
$117.4B
Debt to equity
1.3
PFE's short-term assets ($45.86B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PFE's long-term liabilities ($80.94B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PFE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.3B
Investing
$3.3B
Financing
-$5.2B
PFE's operating cash flow ($13.99B)... subscribe to Premium to read more.
Debt Coverage Financials
PFE vs General Drug Manufacturer Stocks
Pfizer Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.